What is Cyclophosphamide?
Category: Prescription Drugs
Most popular types: Cytoxan HiCY (High Intensity Cytoxan) Endoxan
See also: Bortezomib-cyclophosphamide-dexamethasone (VCd or CyBorD) Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide (VTD-PACE) CALGB 9251 Carfilzomib-cyclophosphamide-dexamethasone CEF protocol CODOX-M/IVAC Cyclophosphamide-lenalidomide-dexamethasone Cyclophosphamide-methotrexate-fluorouracil (CMF) Dexamethasone-cyclophosphamide-etoposide-cisplatin (DCEP) Dexamethasone-thalidomide-cisplatin-doxorubicin-cyclophosphamide-etoposide (DT-PACE) Docetaxel-cyclophosphamide (TC) Docetaxel-doxorubicin-cyclophosphamide (TAC) Doxorubicin-cyclophosphamide (AC) Doxorubicin-cyclophosphamide-docetaxel-trastuzumab Doxorubicin-cyclophosphamide-docetaxel-trastuzumab-pertuzumab Doxorubicin-cyclophosphamide-paclitaxel (ACT) Doxorubicin-cyclphophosphamide-paclitaxel-trastuzumab (AC-TH) Doxorubicin-cyclphophosphamide-paclitaxel-trastuzumab-pertuzumab (AC-THP) DRC protocol Epirubicin-cyclophosphamide EPOCH FAC protocol FCMR protocol FEC-100 protocol ILD Phase II/III Rituximab Versus Cyclophosphamide RECITAL Study R-CVP protocol
Cyclophosphamide is a nitrogen mustard alkylating agent that is used to treat various types of cancer. It is also used to prevent transplant rejection and autoimmune disorders; rheumatoid disorders, myasthenia gravis, nephrotic syndrome, multiple scelrosis, lupus and certain blood disorders.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Systemic lupus erythematosus | 713 | 18 | |
| Lupus nephritis | 152 | 9 | |
| Multiple sclerosis | 79 | 46 | |
| Chronic lymphocytic leukemia | 67 | 1 | |
| Granulomatosis with polyangiitis (Wegener's) | 55 | 7 | |
| Interstitial lung disease | 27 | 6 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 19 | |
| Moderate | 46 | |
| Mild | 37 | |
| None | 13 |
Commonly reported side effects and conditions associated with Cyclophosphamide
| Side effect | Patients | Percentage |
|---|---|---|
| Nausea | 27 | |
| Fatigue | 14 | |
| Hair loss | 12 | |
| Constipation | 7 | |
| Hair thinning | 5 | |
| Vomiting | 4 |
Why patients stopped taking Cyclophosphamide
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Course of treatment ended | 89 | |
| Doctor's advice | 31 | |
| Did not seem to work | 30 | |
| Side effects too severe | 22 | |
| Other | 13 | |
| Personal research | 3 | |
| Expense | 1 |
Duration
Stopped taking Cyclophosphamide
| Duration | Patients | Percentage |
|---|---|---|
| Less than 1 month | 21 | |
| 1 - 6 months | 49 | |
| 6 months - 1 year | 32 | |
| 1 - 2 years | 24 | |
| 2 - 5 years | 13 | |
| 5 - 10 years | 6 | |
| 10 years or more | 3 |
What people switch to and from
Patients started taking Cyclophosphamide after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Mycophenolate mofetil (CellCept) | 7 | |
| Azathioprine (Imuran) | 4 | |
| Methotrexate (Apo-Methotrexate) | 3 | |
| Interferon beta-1a IM Injection (Avonex) | 2 | |
| Lenalidomide (Revlimid) | 2 |
Patients stopped taking Cyclophosphamide and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Mycophenolate mofetil (CellCept) | 6 | |
| Rituximab (Rituxan) | 4 | |
| Azathioprine (Imuran) | 2 | |
| Belimumab (Benlysta) | 2 | |
| Hydroxychloroquine (Plaquenil) | 2 |